KYMR

Kymera Therapeutics Inc

117.39

Sep 04 • 3:59 PM ET +0.11 (0.09%)

117.39

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Peers: BMRN INCY KRYS AXSM CRNX CYTK MDGL VKTX KROS NBIX

| Held by: VTI IWM XBI VB VBK VXF IBB IWO VTWO TCAF

Index	RUT
Market Cap	9.76B
Enterprise Value	9.15B
Income	-299.60M
Sales	105.00M
Book/sh	18.23
Cash/sh	8.31
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	238
IPO	Aug 21, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	92.96
P/B	6.44
P/C	14.13
P/FCF	-
EV/EBITDA	-
EV/Sales	87.13
Quick Ratio	10.34
Current Ratio	10.34
Debt/Eq	0.05
LT Debt/Eq	0.04
Option/Short	Yes / Yes

EPS (ttm)	-3.24
EPS next Y	-4.97
EPS next Q	-1.25
EPS this Y	-3.65%
EPS next Y	-30.03%
EPS next 5Y	-12.58%
EPS past 3/5Y	-8.68% -3.19%
Sales past 3/5Y	-5.74% 2.87%
EPS Y/Y TTM	6.73%
Sales Y/Y TTM	134.84%
EPS Q/Q	34.53%
Sales Q/Q	466.40%
Earnings	Aug 05 BMO
EPS/Sales Surpr.	12.99% 98.32%

Insider Own	10.23%
Insider Trans	-31.20%
Inst Own	108.47%
Inst Trans	-6.35%
ROA	-21.58%
ROE	-24.15%
ROIC	-19.03%
Gross Margin	92.16%
Oper. Margin	-329.83%
Profit Margin	-285.34%
SMA20	-1.28%
SMA50	2.93%
SMA200	31.77%
Trades

Shs Outstand	82.79M
Shs Float	74.64M
Short Float	13.91%
Short Ratio	12.17
Short Interest	10.38M
52W High	130.05 -9.73%
52W Low	40.70 188.43%
Volatility	3.95% 4.07%
ATR (14)	4.93
RSI (14)	51.78
Beta	1.98
Rel Volume	0.44
Avg Volume	852.86K
Volume	378,568

Perf Week	-0.64%
Perf Month	10.32%
Perf Quarter	58.36%
Perf Half Y	40.60%
Perf YTD	50.87%
Perf Year	178.18%
Perf 3Y	491.09%
Perf 5Y	95.52%
Perf 10Y	-
Recom	1.30
Target Price	134.71
Prev Close	117.28
Price	117.39
Change %	0.09%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-30-26	Initiated	Deutsche Bank	Hold	$120
May-06-26	Initiated	Canaccord Genuity	Buy	$106
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Resumed	Barclays	Overweight	$133
Jan-06-26	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-03-25	Resumed	Guggenheim	Buy	$90
Oct-24-25	Reiterated	B. Riley Securities	Buy	$60 → $80
Oct-21-25	Initiated	Mizuho	Outperform	$81
Sep-18-25	Reiterated	H.C. Wainwright	Buy	$60 → $70
Sep-17-25	Initiated	Barclays	Overweight	$60
Sep-16-25	Initiated	RBC Capital Mkts	Outperform	$70
Jul-30-25	Resumed	B. Riley Securities	Buy	$60
Jul-03-25	Resumed	Morgan Stanley	Overweight	$70
Jun-03-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$79
Jun-03-25	Upgrade	B. Riley Securities	Neutral → Buy	$60
Jun-02-25	Upgrade	BofA Securities	Neutral → Buy	$51
May-20-25	Resumed	Stifel	Buy	$55
Mar-13-25	Initiated	Citigroup	Buy	$52
Dec-10-24	Initiated	BTIG Research	Buy	$60
Dec-06-24	Initiated	BMO Capital Markets	Market Perform	$55

Show Previous Ratings

Sep-02-26 04:01PM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Sep-01-26 07:00AM	Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses (GlobeNewswire)
Aug-05-26 06:01PM	Kymera Therapeutics, Inc. Q2 2026 Earnings Call Summary (Moby)
07:00AM	Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-04-26 09:23AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Q2 2026 -- GF Value Sees 80% Downside (GuruFocus.com)
09:38AM	Loading…
Jul-30-26 09:38AM	Humana upgraded, Las Vegas Sands downgraded: Wall Street's top analyst calls (The Fly)
Jul-28-26 04:01PM	Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026 (GlobeNewswire)
Jul-27-26 04:01PM	Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer (GlobeNewswire)
Jul-13-26 09:41AM	American Express, Biogen upgraded: Wall Street's top analyst calls (The Fly) -7.50%
Jul-07-26 07:00AM	Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Jul-03-26 04:00AM	Alkami Technology, Diebold Nixdorf, and 3 More Stocks See Action From Activist Investors. (Barrons.com)
Jun-25-26 07:58PM	KYMR Stock Clocks Best Day In Over 6 Months On Advancing Eczema Trial Timeline (Stocktwits) +16.61% -7.16%
11:16AM	Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi? (Investor's Business Daily)
07:00AM	Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026 (GlobeNewswire)
Jun-24-26 04:01PM	Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors (GlobeNewswire)
07:00AM	Loading…
Jun-12-26 07:00AM	Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting (GlobeNewswire)
Jun-09-26 07:00AM	Kymera Therapeutics Announces First Participant Dosed in Phase 1 Trial of Oral IRAK4 Degrader, KT-485, and Milestone Achievement Under Sanofi Collaboration (GlobeNewswire)
Jun-08-26 04:01PM	Kymera Therapeutics Appoints Penny Carlson as Senior Vice President, Development Operations (GlobeNewswire)
07:00AM	Kymera Therapeutics Presents New Preclinical Lupus Data for KT-579, First-in-Class, Oral IRF5 Degrader, at EULAR and FOCIS Congresses (GlobeNewswire)
May-27-26 07:00AM	Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-26 07:00AM	Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses (GlobeNewswire)
May-06-26 09:38AM	AMD upgraded, Reddit downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Kymera Therapeutics to Participate in Upcoming May Investor Conferences (GlobeNewswire)
May-05-26 07:00AM	Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week (GlobeNewswire)
Apr-30-26 07:00AM	Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-29-26 09:20AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q1 2026 Result (GuruFocus.com)
Apr-23-26 07:00AM	Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026 (GlobeNewswire)
Apr-13-26 07:00AM	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma (GlobeNewswire)
Apr-09-26 07:00AM	Kymera Therapeutics Announces Gilead Sciences' Option Exercise to License KT-200, Oral CDK2 Molecular Glue Degrader Development Candidate (GlobeNewswire)
Mar-28-26 11:00AM	Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
08:15AM	Loading…
Mar-23-26 08:15AM	Apogee strengthens case for longer-lasting eczema drug (BioPharma Dive)
Mar-10-26 07:00AM	Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting (GlobeNewswire)
Mar-09-26 10:38PM	Kymera CEO Nello Mainolfi's Boldest Line Had Nothing to Do With the Earnings Miss (24/7 Wall St.)
Feb-28-26 01:32PM	Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 (MarketBeat)
Feb-27-26 09:34AM	Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway (Zacks)
09:00AM	Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler (TipRanks)
Feb-26-26 05:03PM	Kymera Therapeutics Q4 Earnings Call Highlights (MarketBeat)
04:08PM	Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com)
09:55AM	Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Feb-25-26 07:19AM	Kymera Therapeutics Inc (KYMR) Q4 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Feb-24-26 07:00AM	Kymera Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Feb-19-26 07:00AM	Kymera Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 (GlobeNewswire)
Feb-14-26 01:03AM	Kymera Therapeutics Touts Once-Daily Oral Biologics-Like KT-621 at Guggenheim Conference (MarketBeat)
Feb-04-26 07:00AM	Kymera Therapeutics to Participate in Upcoming February Investor Conferences (GlobeNewswire)
Jan-30-26 10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Jan-15-26 11:35AM	Kymera Therapeutics, Inc. (KYMR) Up 28% in 3M, Analysts See Further Upside (Insider Monkey) -5.44%
Jan-13-26 07:00AM	Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs (GlobeNewswire)
Jan-12-26 12:00PM	Kymera Therapeutics (KYMR) Upgraded to Buy: Here's Why (Zacks)
Jan-06-26 07:00AM	Kymera Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 (GlobeNewswire)
Jan-05-26 01:45PM	KYMR Skyrockets 82.4% in a Year: More Upside Potential in 2026? (Zacks)
Jan-01-26 11:35AM	Insider Buying: Smart Money Just Spent +$100M on These 3 Stocks (MarketBeat)
Dec-30-25 08:45AM	The Biggest IPO of the Year Prompts Huge Insider Buy (24/7 Wall St.)
Dec-17-25 09:45AM	Share Offerings Prompt Huge Insider Buying in These 3 Biotechs (24/7 Wall St.)
Dec-14-25 03:30AM	Kymera Had a Big Week. This Secretive Hedge Fund Bought $172 Million of Its Stock. (Barrons.com)
Dec-12-25 10:30AM	Kymera's Eczema Drug Gets Fast Track Designation in the United States (Zacks)
Dec-11-25 04:01PM	Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
07:00AM	Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis (GlobeNewswire)
Dec-09-25 11:30PM	Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering (GlobeNewswire) -7.87%
02:23PM	Kymera (KYMR) Jumps to All-Time High as Eczema Treatment Results Impress (Insider Monkey)
10:43AM	KYMR Stock Surges on Upbeat Data From KT-621 Atopic Dermatitis Study (Zacks)
Dec-08-25 04:09PM	Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent? (Investor's Business Daily) +41.55%
04:01PM	Kymera Therapeutics Announces Proposed Public Offering (GlobeNewswire)
03:10PM	This Drugmaker's Stock Is Soaring Over 40% Monday (Investopedia)
01:07PM	Kymera Therapeutics Stock Heads for Record. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:42AM	Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. (Barrons.com)
07:00AM	Kymera Therapeutics Announces Positive Results from BroADen Phase 1b Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader, in Patients with Moderate to Severe Atopic Dermatitis (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-05-25 04:01PM	Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 (GlobeNewswire)
11:30AM	Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report? (Zacks)
Dec-04-25 11:30AM	Kymera Therapeutics (KYMR) Up 10.2% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-26-25 07:33AM	Kymera Trades Near 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
Nov-25-25 07:00AM	Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader (GlobeNewswire)
Nov-24-25 07:00AM	Kymera Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-04-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-03-25 07:26AM	Kymera Therapeutics Inc (KYMR) Q3 2025 Earnings Report Preview: What to Look For (GuruFocus.com)
07:00AM	Kymera Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-28-25 07:00AM	Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-27-25 10:00AM	TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release (Zacks)
07:00AM	Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting (GlobeNewswire)
Oct-23-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) May Report Negative Earnings: Know the Trend Ahead of Q3 Release (Zacks)
Oct-01-25 09:38AM	Kymera Overcomes Sanofi Deal Update, Marches Ahead With Pipeline (Zacks)
Sep-17-25 07:00AM	Kymera Therapeutics Announces Late-Breaking Oral Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the European Academy of Dermatology & Venereology and European Respiratory Society Congresses (GlobeNewswire)
Sep-16-25 12:30PM	Kymera initiated at Outperform on potential of lead skin drug (Investing.com)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-07-25 10:08AM	Why Kymera (KYMR) Could Be One of Biotech's Most Interesting Growth Stories? (Insider Monkey)
Sep-03-25 07:00AM	Kymera Therapeutics Appoints Brian Adams as Chief Legal Officer and Corporate Secretary (GlobeNewswire) +6.41%
Aug-27-25 07:00AM	Kymera Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-12-25 03:04AM	Kymera Therapeutics Inc (KYMR) Q2 2025 Earnings Call Highlights: Strategic Collaborations and ... (GuruFocus.com) +5.81%
Aug-11-25 08:10AM	Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -7.24%
07:00AM	Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-25 09:23AM	GILD Stock Rises on Q2 Earnings and Sales Beat, '25 View Up (Zacks)
09:20AM	Earnings To Watch: Kymera Therapeutics Inc (KYMR) Reports Q2 2025 Result (GuruFocus.com)
Aug-06-25 10:00AM	CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Q2 Release (Zacks)
Aug-04-25 07:00AM	Kymera Therapeutics to Report Second Quarter 2025 Financial Results on August 11, 2025 (GlobeNewswire)
Jul-30-25 10:00AM	Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release (Zacks)
Jul-18-25 09:54AM	Kymera Surges 70% in 3 Months: Buy, Sell or Hold the Stock? (Zacks)
Jul-10-25 12:39AM	Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating (Insider Monkey)

Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.

Ph.D.Dr. Nello Mainolfi M.D.

Chief Financial OfficerMr. Bruce N. Jacobs CFA

Chief Legal Officer & Corporate SecretaryMr. Brian R. Adams J.D.

AdvisorDr. Jared A. Gollob M.D.

Chief Business OfficerMr. Noah Goodman M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adams Brian	Chief Legal Officer	Sep 04 '26	Sale	116.83	6,371	744,297	50,254	Sep 04 06:00 PM
Brian Adams	Officer	Sep 04 '26	Proposed Sale	117.28	6,371	747,191		Sep 04 04:15 PM
JEREMY CHADWICK	Officer	Sep 02 '26	Proposed Sale	119.05	10,879	1,295,145		Sep 02 04:32 PM
Mainolfi Nello	Chief Executive Officer	Jul 07 '26	Option Exercise	2.08	50,000	104,000	716,568	Jul 07 08:00 PM
Mainolfi Nello	Chief Executive Officer	Jul 07 '26	Sale	119.00	50,000	5,950,000	666,568	Jul 07 08:00 PM
Mainolfi Nello	Officer	Jul 07 '26	Proposed Sale	119.00	50,000	5,950,000		Jul 07 04:07 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 30 '26	Option Exercise	5.33	61,378	327,145	321,992	Jul 02 06:30 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 30 '26	Sale	114.96	77,109	8,864,829	244,883	Jul 02 06:30 PM
Goodman Noah	Chief Business Officer	Jul 01 '26	Sale	114.29	3,389	387,329	47,179	Jul 02 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jul 01 '26	Option Exercise	2.08	80,000	166,400	746,568	Jul 02 06:30 PM
Mainolfi Nello	Chief Executive Officer	Jul 01 '26	Sale	115.29	80,000	9,223,527	666,568	Jul 02 06:30 PM
Mainolfi Nello	Officer	Jul 01 '26	Proposed Sale	114.29	80,000	9,143,200		Jul 02 08:33 AM
NOAH GOODMAN	Officer	Jul 01 '26	Proposed Sale	114.67	3,389	388,617		Jul 01 04:58 PM
Booth Bruce	Director	Jun 29 '26	Sale	109.48	31,283	3,424,800	461,794	Jun 30 05:32 PM
Booth Bruce	Director	Jun 26 '26	Sale	110.29	467,878	51,603,032	472,267	Jun 30 05:30 PM
Booth Bruce	Director	Jun 29 '26	Sale	107.06	45,367	4,857,104	466,077	Jun 30 05:30 PM
BRUCE N. JACOBS	Officer	Jun 30 '26	Proposed Sale	109.32	77,109	8,429,556		Jun 30 04:32 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 29 '26	Proposed Sale	108.12	10,473	1,132,341		Jun 29 05:51 PM
Atlas Venture Fund X, LP	Shareholder	Jun 29 '26	Proposed Sale	108.12	66,177	7,155,057		Jun 29 05:51 PM
BVF PARTNERS L P/IL	Director	Jun 26 '26	Sale	106.50	1,578,800	168,142,200	240,123	Jun 26 06:48 PM
BVF PARTNERS L P/IL	Director	Jun 26 '26	Sale	106.50	51,858	5,522,877	78,787	Jun 26 06:48 PM
BVF PARTNERS L P/IL	Affiliate of Director	Jun 26 '26	Proposed Sale	116.46	1,630,658	189,906,431		Jun 26 06:13 PM
Atlas Venture Fund X, LP	Shareholder	Jun 26 '26	Proposed Sale	116.46	410,427	47,798,328		Jun 26 04:52 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 26 '26	Proposed Sale	116.46	57,451	6,690,743		Jun 26 04:51 PM
Booth Bruce	Director	Jun 25 '26	Sale	121.86	285,684	34,812,909	529,718	Jun 25 09:56 PM
Booth Bruce	Director	Jun 25 '26	Sale	115.39	262,637	30,306,107	564,668	Jun 25 09:55 PM
Booth Bruce	Director	Jun 24 '26	Sale	100.51	134,720	13,540,476	597,047	Jun 25 09:55 PM
Booth Bruce	Director	Jun 23 '26	Sale	99.98	1,408	140,772	613,589	Jun 25 09:55 PM
Goodman Noah	Chief Business Officer	Jun 25 '26	Option Exercise	21.05	5,000	105,250	55,195	Jun 25 06:00 PM
Goodman Noah	Chief Business Officer	Jun 25 '26	Sale	114.00	5,000	570,000	50,195	Jun 25 06:00 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 25 '26	Proposed Sale	99.87	67,329	6,724,147		Jun 25 05:26 PM
Atlas Venture Fund X, LP	Shareholder	Jun 25 '26	Proposed Sale	99.87	480,992	48,036,671		Jun 25 05:25 PM
NOAH GOODMAN	Officer	Jun 25 '26	Proposed Sale	99.87	5,000	499,350		Jun 25 04:27 PM
Atlas Venture Fund X, LP	Shareholder	Jun 24 '26	Proposed Sale	98.25	118,178	11,610,988		Jun 24 05:30 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 24 '26	Proposed Sale	98.25	16,542	1,625,252		Jun 24 05:29 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 23 '26	Proposed Sale	99.45	173	17,205		Jun 23 06:14 PM
Atlas Venture Fund X, LP	Shareholder	Jun 23 '26	Proposed Sale	99.45	1,235	122,821		Jun 23 06:14 PM
Booth Bruce	Director	Jun 22 '26	Sale	103.75	31,798	3,299,037	613,762	Jun 22 09:02 PM
Booth Bruce	Director	Jun 17 '26	Option Exercise	20.00	11,741	234,820	11,741	Jun 22 09:01 PM
Booth Bruce	Director	Jun 22 '26	Sale	98.52	246,330	24,268,861	617,663	Jun 22 09:01 PM
Booth Bruce	Director	Jun 18 '26	Sale	91.01	115,056	10,471,661	647,914	Jun 22 09:01 PM
Booth Bruce	Director	Jun 17 '26	Sale	90.38	105,071	9,496,317	662,042	Jun 22 09:01 PM
Booth Bruce	Director	Jun 17 '26	Sale	89.98	11,741	1,056,455	0	Jun 22 09:01 PM
Goodman Noah	Chief Business Officer	Jun 22 '26	Option Exercise	21.05	2,500	52,625	52,695	Jun 22 05:47 PM
Goodman Noah	Chief Business Officer	Jun 22 '26	Sale	99.00	2,500	247,500	50,195	Jun 22 05:47 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 22 '26	Proposed Sale	90.43	34,152	3,088,365		Jun 22 05:28 PM
Atlas Venture Fund X, LP	Shareholder	Jun 22 '26	Proposed Sale	90.43	243,976	22,062,750		Jun 22 05:28 PM
NOAH GOODMAN	Officer	Jun 22 '26	Proposed Sale	90.43	2,500	226,075		Jun 22 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 18 '26	Proposed Sale	89.90	14,128	1,270,107		Jun 18 05:35 PM
Atlas Venture Fund X, LP	Shareholder	Jun 18 '26	Proposed Sale	89.90	100,928	9,073,427		Jun 18 05:35 PM
Atlas Venture Opportunity Fund	Shareholder	Jun 17 '26	Proposed Sale	87.44	12,902	1,128,151		Jun 17 05:26 PM
Atlas Venture Fund X, LP	Shareholder	Jun 17 '26	Proposed Sale	87.44	92,169	8,059,257		Jun 17 05:25 PM
Bruce Booth	Director	Jun 17 '26	Proposed Sale	87.44	11,741	1,026,633		Jun 17 05:25 PM
JEREMY CHADWICK	Officer	Jun 17 '26	Proposed Sale	87.44	66,893	5,849,124		Jun 17 04:43 PM
Jacobs Bruce N.	Chief Financial Officer	Jun 02 '26	Option Exercise	2.08	12,653	26,318	260,241	Jun 03 07:30 AM
Chadwick Jeremy G	Chief Operating Officer	May 26 '26	Sale	79.36	12,905	1,024,194	48,297	May 27 05:50 PM
Chadwick Jeremy G	Chief Operating Officer	May 27 '26	Sale	81.58	4,279	349,096	44,018	May 27 05:50 PM
JEREMY CHADWICK	Officer	May 26 '26	Proposed Sale	78.89	13,130	1,035,826		May 26 04:41 PM
Chadwick Jeremy G	Officer	May 26 '26	Proposed Sale	78.42	4,054	317,922		May 26 04:01 PM
Esposito Pamela	Director	May 19 '26	Option Exercise	31.20	1,000	31,200	1,000	May 19 04:05 PM
Jacobs Bruce N.	Chief Financial Officer	May 18 '26	Option Exercise	2.08	15,000	31,200	247,588	May 19 07:30 AM
Ridloff Elena	Director	May 11 '26	Option Exercise	31.20	3,000	93,600	3,000	May 11 04:58 PM
Ridloff Elena	Director	May 11 '26	Sale	87.00	3,000	261,000	0	May 11 04:58 PM
ELENA RIDLOFF	Director	May 11 '26	Proposed Sale	86.08	3,000	258,240		May 11 04:35 PM
Mainolfi Nello	Chief Executive Officer	Apr 29 '26	Option Exercise	2.08	30,000	62,400	696,195	Apr 29 05:00 PM
Mainolfi Nello	Chief Executive Officer	Apr 29 '26	Sale	81.18	30,000	2,435,377	666,195	Apr 29 05:00 PM
Mainolfi Nello	Officer	Apr 29 '26	Proposed Sale	82.47	30,000	2,474,100		Apr 29 04:07 PM
Booth Bruce	Director	Apr 22 '26	Option Exercise	14.44	5,900	85,169	5,900	Apr 24 04:33 PM
Booth Bruce	Director	Apr 22 '26	Sale	89.96	5,900	530,764	0	Apr 24 04:33 PM
Booth Bruce	Director	Apr 22 '26	Sale	90.08	100	9,008	674,944	Apr 24 04:33 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 22 '26	Option Exercise	39.06	300	11,717	61,502	Apr 24 04:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 22 '26	Sale	90.00	300	27,000	61,202	Apr 24 04:30 PM
Atlas Venture Fund X, LP	Shareholder	Apr 22 '26	Proposed Sale	88.07	88	7,750		Apr 22 04:52 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 22 '26	Proposed Sale	88.07	12	1,057		Apr 22 04:52 PM
JEREMY CHADWICK	Officer	Apr 22 '26	Proposed Sale	88.07	300	26,421		Apr 22 04:30 PM
Goodman Noah	Chief Business Officer	Apr 14 '26	Sale	90.00	1,347	121,230	50,195	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 14 '26	Option Exercise	32.16	5,251	168,887	66,453	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 15 '26	Option Exercise	43.50	1,300	56,550	62,502	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 14 '26	Sale	90.00	5,251	472,598	61,202	Apr 16 06:30 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 15 '26	Sale	90.00	1,300	117,000	61,202	Apr 16 06:30 PM
Booth Bruce	Director	Apr 14 '26	Option Exercise	14.18	4,159	58,975	4,159	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Option Exercise	14.18	2,200	31,196	2,200	Apr 16 06:16 PM
Booth Bruce	Director	Apr 14 '26	Sale	89.97	4,159	374,185	0	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Sale	90.10	3,135	282,464	674,956	Apr 16 06:16 PM
Booth Bruce	Director	Apr 15 '26	Sale	89.95	2,200	197,890	0	Apr 16 06:16 PM
Atlas Venture Opportunity Fund	Shareholder	Apr 15 '26	Proposed Sale	89.87	385	34,600		Apr 15 04:51 PM
Atlas Venture Fund X, LP	Shareholder	Apr 15 '26	Proposed Sale	89.87	2,750	247,142		Apr 15 04:51 PM
JEREMY CHADWICK	Officer	Apr 15 '26	Proposed Sale	89.86	1,300	116,824		Apr 15 04:41 PM
Bruce Booth	Director	Apr 14 '26	Proposed Sale	88.53	24,000	2,124,720		Apr 14 05:19 PM
JEREMY CHADWICK	Officer	Apr 14 '26	Proposed Sale	88.53	5,251	464,871		Apr 14 04:37 PM
Goodman Noah	Chief Business Officer	Apr 09 '26	Option Exercise	21.05	2,500	52,625	61,806	Apr 10 04:45 PM
Goodman Noah	Chief Business Officer	Apr 09 '26	Sale	87.50	8,264	723,082	53,542	Apr 10 04:45 PM
Goodman Noah	Chief Business Officer	Apr 10 '26	Sale	87.35	2,000	174,700	51,542	Apr 10 04:45 PM
Noah Goodman	Officer	Apr 09 '26	Proposed Sale	87.35	11,611	1,014,221		Apr 09 04:28 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 01 '26	Option Exercise	29.64	14,640	433,930	75,842	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 31 '26	Option Exercise	29.64	7,600	225,264	68,802	Apr 01 07:00 PM
Ridloff Elena	Director	Mar 31 '26	Option Exercise	14.18	7,400	104,932	7,400	Apr 01 07:00 PM
Ridloff Elena	Director	Apr 01 '26	Option Exercise	14.18	4,600	65,228	4,600	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Apr 01 '26	Sale	85.46	14,640	1,251,166	61,202	Apr 01 07:00 PM
Chadwick Jeremy G	Chief Operating Officer	Mar 31 '26	Sale	85.38	7,600	648,882	61,202	Apr 01 07:00 PM

Open in Screener

RLAY

Relay Therapeutics Inc

19.04

Sep 04 • 3:59 PM ET +0.03 (0.16%)

19.04

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

RLAY Relay Therapeutics Inc daily Stock Chart

Peers: IDYA RCUS RYTM KYMR AXSM BMRN CRNX INCY APGE KRYS

| Held by: VTI XBI IWM VXF IBB IWO VTWO SCHA DFAS FYC

Index	RUT
Market Cap	4.17B
Enterprise Value	3.29B
Income	-286.04M
Sales	10.35M
Book/sh	4.07
Cash/sh	4.16
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	192
IPO	Jul 16, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	403.13
P/B	4.68
P/C	4.58
P/FCF	-
EV/EBITDA	-
EV/Sales	318.08
Quick Ratio	18.27
Current Ratio	18.27
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-1.57
EPS next Y	-1.62
EPS next Q	-0.40
EPS this Y	0.35%
EPS next Y	-0.73%
EPS next 5Y	-0.23%
EPS past 3/5Y	14.61% 8.85%
Sales past 3/5Y	123.20% -28.58%
EPS Y/Y TTM	19.60%
Sales Y/Y TTM	23.86%
EPS Q/Q	-0.44%
Sales Q/Q	-48.30%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-4.83% -63.54%

Insider Own	21.85%
Insider Trans	-12.01%
Inst Own	98.99%
Inst Trans	23.13%
ROA	-33.72%
ROE	-36.77%
ROIC	-31.20%
Gross Margin	78.64%
Oper. Margin	-2999.37%
Profit Margin	-2763.64%
SMA20	-2.95%
SMA50	-1.63%
SMA200	46.88%
Trades

Shs Outstand	218.53M
Shs Float	171.25M
Short Float	24.15%
Short Ratio	13.13
Short Interest	41.36M
52W High	21.27 -10.48%
52W Low	3.86 393.90%
Volatility	4.00% 4.49%
ATR (14)	0.92
RSI (14)	47.77
Beta	1.73
Rel Volume	0.65
Avg Volume	3.15M
Volume	2,054,847

Perf Week	1.44%
Perf Month	-3.59%
Perf Quarter	40.83%
Perf Half Y	92.52%
Perf YTD	125.06%
Perf Year	376.00%
Perf 3Y	72.62%
Perf 5Y	-39.56%
Perf 10Y	-
Recom	1.07
Target Price	27.08
Prev Close	19.01
Price	19.04
Change %	0.16%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-16-26	Initiated	Canaccord Genuity	Buy	$29
Jul-08-26	Initiated	JP Morgan	Overweight	$28
Jan-26-26	Upgrade	Oppenheimer	Perform → Outperform	$14
Dec-12-25	Upgrade	Wells Fargo	Equal Weight → Overweight	$13
Sep-04-25	Resumed	Guggenheim	Buy	$15
Apr-17-25	Initiated	Wells Fargo	Equal Weight	$4
Sep-10-24	Upgrade	Jefferies	Hold → Buy	$10.60 → $16
Sep-10-24	Resumed	Goldman	Buy	$20
Sep-10-24	Downgrade	Oppenheimer	Outperform → Perform
May-10-24	Upgrade	Barclays	Equal Weight → Overweight	$15
Apr-20-23	Upgrade	Jefferies	Underperform → Hold	$12.50
Apr-19-23	Upgrade	Raymond James	Outperform → Strong Buy	$29
Apr-13-23	Initiated	Raymond James	Outperform	$29
Feb-03-23	Initiated	Oppenheimer	Outperform	$33
Sep-30-22	Initiated	Barclays	Equal Weight	$23
Sep-02-22	Initiated	Stifel	Buy	$40
Jun-06-22	Initiated	Jefferies	Underperform	$13
Feb-01-22	Initiated	Berenberg	Buy	$45
Jul-21-21	Initiated	BofA Securities	Buy	$50
Dec-15-20	Reiterated	H.C. Wainwright	Buy	$54 → $57

Show Previous Ratings

Sep-01-26 04:46PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
Aug-20-26 08:03AM	This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion (Investor's Business Daily) -5.01%
Aug-06-26 04:05PM	Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates (GlobeNewswire)
Jul-30-26 04:05PM	Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 (GlobeNewswire) +5.88%
Jul-23-26 09:05AM	An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers (PR Newswire)
04:05PM	Loading…
May-27-26 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June (GlobeNewswire)
May-20-26 08:21PM	Relay Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) +7.87%
May-19-26 04:03PM	Relay Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
09:31AM	Relay Therapeutics shares jump after positive vascular anomalies trial results (RLAY) (InvestorsHub)
06:02AM	This Biotech's Drug Just Wiped The Floor With Forecasts (Investor's Business Daily)
06:00AM	Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies (GlobeNewswire)
04:05AM	Relay drug shows early promise against rare blood vessel diseases (BioPharma Dive)
May-05-26 04:05PM	Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates (GlobeNewswire)
Apr-29-26 04:05PM	Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026 (GlobeNewswire)
Apr-27-26 06:00AM	Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer (GlobeNewswire)
04:05PM	Loading…
Apr-02-26 04:05PM	Relay Therapeutics to Present Initial Clinical Data on Zovegalisib in Vascular Anomalies at the International Society for the Study of Vascular Anomalies World Congress 2026 (GlobeNewswire) +16.43%
Mar-16-26 07:00AM	Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 (GlobeNewswire)
Feb-26-26 06:00PM	Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +12.01%
04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones (GlobeNewswire)
Feb-23-26 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March (GlobeNewswire)
Feb-19-26 05:55PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 (GlobeNewswire)
Feb-05-26 09:35AM	$207B Market Shift: The Race for Fast Track Approval in Oncology (PR Newswire)
Feb-04-26 04:05PM	Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
06:27AM	Relay Therapeutics' zovegalisib secures FDA BTD for advanced breast cancer (Pharmaceutical Business Review)
Feb-03-26 07:00AM	Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer (GlobeNewswire) +6.38%
Feb-02-26 09:51AM	Oppenheimer Notes Relay Therapeutics, Inc. (RLAY) Pipeline Strength in Mutant-Selective Inhibitors (Insider Monkey) +6.40%
Dec-12-25 07:00AM	Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 (GlobeNewswire)
Nov-11-25 10:10AM	Theravance's Q3 Earnings Surpass Estimates, Revenues Match (Zacks)
09:56AM	IRWD Beats on Q3 Earnings & Revenues, Raises 2025 View, Stock Soars (Zacks)
Nov-06-25 04:05PM	Relay Therapeutics Reports Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire) -7.35%
04:05PM	Loading…
Nov-03-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in November (GlobeNewswire)
Oct-30-25 04:05PM	Relay Therapeutics to Announce Third Quarter 2025 Financial Results and Corporate Highlights on November 6, 2025 (GlobeNewswire)
09:55AM	Wall Street Analysts Think Relay Therapeutics (RLAY) Could Surge 86.05%: Read This Before Placing a Bet (Zacks)
Oct-28-25 12:00PM	Here's Why Relay Therapeutics, Inc. (RLAY) is a Great Momentum Stock to Buy (Zacks)
11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-14-25 09:55AM	Wall Street Analysts Believe Relay Therapeutics (RLAY) Could Rally 116.91%: Here's is How to Trade (Zacks)
Sep-21-25 09:25AM	Relay Therapeutics, Inc. (RLAY) Shows Breakthrough Breast Cancer Results With RLY-2608 (Insider Monkey)
Sep-08-25 09:42AM	Investing in Oncology: 3 Cancer Stocks With Promising Pipelines (Zacks)
12:30AM	Guggenheim Gives Buy Rating to Relay Therapeutics (RLAY) (Insider Monkey)
Sep-05-25 06:42PM	Why Relay Therapeutics Stock Rocketed Nearly 15% Higher This Week (Motley Fool)
Aug-28-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in September (GlobeNewswire)
Aug-25-25 11:56PM	Leerink Partners Reiterates a Buy Rating on Relay Therapeutics (RLAY) With a $12 PT (Insider Monkey)
Aug-17-25 11:41PM	Raymond James Lowers Relay Therapeutics (RLAY) PT to $19 Following Q2 Results, Strategic Cost Cuts (Insider Monkey)
Aug-12-25 12:00PM	Relay Therapeutics (RLAY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-07-25 06:35PM	Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -7.74%
04:05PM	Relay Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Aug-04-25 10:01AM	Barclays Maintains a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT (Insider Monkey) +8.63%
Jul-31-25 04:05PM	Relay Therapeutics to Announce Second Quarter 2025 Financial Results and Corporate Highlights on August 7, 2025 (GlobeNewswire)
Jul-29-25 09:56AM	Relay Therapeutics has positive read from Celcuity data, says Barclays (TipRanks)
Jul-25-25 11:33AM	RXRX vs. RLAY: Which Precision Biotech Stock is a Better Bet Now? (Zacks)
Jul-23-25 10:02AM	Can Recent Pipeline Expansion Efforts Offset RXRX's Earlier Losses? (Zacks)
Jul-16-25 09:58AM	Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? (Zacks)
Jul-07-25 10:23AM	Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith? (Zacks)
Jul-02-25 10:28AM	Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process? (Zacks)
Jun-24-25 03:51PM	BofA Reiterates a Buy Rating on Relay Therapeutics (RLAY), Sets a $17 PT (Insider Monkey)
Jun-20-25 09:21AM	With Public Funding Under Pressure, Biotech Innovators Are Picking Up the Slack in Oncology (PR Newswire) -5.06%
Jun-11-25 04:05PM	Relay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors (GlobeNewswire)
Jun-09-25 11:37AM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey)
Jun-02-25 07:00AM	Relay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025 (GlobeNewswire) +6.00%
May-29-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences in June (GlobeNewswire)
May-27-25 09:45AM	Healthcare's Quiet AI Boom Is Creating a New Class of Breakout Contenders (PR Newswire)
May-23-25 12:00PM	What Makes Relay Therapeutics (RLAY) a New Buy Stock (Zacks)
May-13-25 08:49AM	Relay Therapeutics, Inc. (RLAY): One of the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey) -9.00%
May-08-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-07-25 06:58PM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey) -6.35%
May-05-25 04:05PM	Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire) -5.12%
Apr-28-25 04:05PM	Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025 (GlobeNewswire)
Apr-20-25 06:19AM	Relay Therapeutics (RLAY): The Most Promising Penny Stock According to Analysts (Insider Monkey)
Apr-16-25 10:03AM	Is Relay Therapeutics Inc. (NASDAQ:RLAY) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -5.43%
09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-12-25 09:28AM	Relay Therapeutics: Trying To Find That Right Price (Seeking Alpha)
Apr-09-25 09:44AM	Relay Therapeutics, Inc. (RLAY): Among Stocks Under $10 that Will Triple (Insider Monkey) +15.00%
05:00AM	Barbara Weber, M.D., Elected to ITM Supervisory Board (GlobeNewswire)
Mar-31-25 09:56AM	Relay Therapeutics (RLAY) Gets Analyst Boost as AI-Driven Drug Discovery Shines! (Insider Monkey)
Mar-05-25 09:35AM	Down -31.1% in 4 Weeks, Here's Why You Should You Buy the Dip in Relay Therapeutics (RLAY) (Zacks) +6.27%
Feb-26-25 04:05PM	Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates (GlobeNewswire) -13.33%
Feb-25-25 10:48AM	What To Expect From Relay Therapeutics Inc (RLAY) Q4 2024 Earnings (GuruFocus.com) -5.15%
Feb-24-25 04:05PM	Relay Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Feb-19-25 04:05PM	Relay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025 (GlobeNewswire) +6.12%
Jan-24-25 12:09PM	Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays $17 Price Target (Insider Monkey)
Jan-07-25 04:05PM	Relay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-30-24 02:57PM	Is Relay Therapeutics (RLAY) the Best Biotech Penny Stock to Invest in Now? (Insider Monkey)
Dec-20-24 12:00PM	Relay Therapeutics (RLAY) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Dec-13-24 05:49PM	Relay Therapeutics, Inc. (RLAY): A Bull Case Theory (Insider Monkey)
Dec-11-24 06:00AM	Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival (GlobeNewswire) +12.42%
Dec-09-24 04:05PM	Relay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -5.74%
Dec-06-24 09:35AM	After Plunging -30.29% in 4 Weeks, Here's Why the Trend Might Reverse for Relay Therapeutics (RLAY) (Zacks) +7.71%
Dec-05-24 06:51AM	Relay Therapeutics price target lowered to $18 from $19 at Leerink (TipRanks)
Dec-04-24 04:36PM	Why Relay Therapeutics (RLAY) is the Best All-Time Low Stock to Buy Right Now? (Insider Monkey)
Dec-03-24 08:01AM	Elevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors (GlobeNewswire) -6.00%
08:00AM	Relay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors (GlobeNewswire)
Nov-20-24 09:35AM	Down -27.93% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround (Zacks)
Nov-19-24 09:35AM	Down -23.95% in 4 Weeks, Here's Why Relay Therapeutics (RLAY) Looks Ripe for a Turnaround (Zacks)
Nov-07-24 04:05PM	Relay Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 04:05PM	Relay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights (GlobeNewswire) +5.04%
Oct-30-24 04:05PM	Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024 (GlobeNewswire)
Sep-17-24 08:24AM	Strength Seen in Relay Therapeutics (RLAY): Can Its 6.7% Jump Turn into More Strength? (Zacks) -6.29%
Sep-11-24 06:46PM	Why Relay Therapeutics Plummeted by Nearly 14% Today (Motley Fool) -13.83%
Sep-10-24 08:21PM	Relay Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -5.36%
Sep-09-24 04:34PM	Relay Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +52.40%

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

M.B.A.Dr. Sanjiv K. Patel M.A.

Founder & Independent DirectorDr. Mark Murcko Ph.D.

Chief Financial OfficerMr. Thomas Catinazzo

Chief Corporate Development OfficerMr. Peter Rahmer

Ph.D.Dr. Donald A. Bergstrom M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rahmer Peter	See remarks	Aug 26 '26	Sale	20.03	4,508	90,295	223,657	Aug 28 04:43 PM
SVF Pauling (Cayman) Ltd	10% Owner	Aug 25 '26	Sale	19.40	6,000,000	116,400,000	21,904,963	Aug 28 09:01 AM
PETER RAHMER	Officer	Aug 26 '26	Proposed Sale	20.57	50,000	1,028,500		Aug 26 04:15 PM
SVF Pauling (Cayman) Ltd	Stockholder	Aug 25 '26	Proposed Sale	20.57	6,000,000	123,420,000		Aug 25 07:43 PM
Patel Sanjiv	President and CEO	Aug 17 '26	Sale	20.33	48,199	979,886	567,699	Aug 18 04:17 PM
Catinazzo Thomas	Chief Financial Officer	Aug 14 '26	Sale	19.74	17,717	349,734	140,568	Aug 18 04:16 PM
SEKAR KATHIRESAN	Director	Aug 04 '26	Proposed Sale	19.57	42,225	826,466		Aug 04 04:11 PM
SEKAR KATHIRESAN	Director	Jul 31 '26	Proposed Sale	18.79	30,000	563,553		Jul 31 04:05 PM
Catinazzo Thomas	Chief Financial Officer	Jul 28 '26	Sale	18.61	1,459	27,152	158,285	Jul 30 04:13 PM
Rahmer Peter	See remarks	Jul 28 '26	Sale	18.61	748	13,920	228,165	Jul 30 04:13 PM
Bergstrom Donald A	President, R&D	Jul 28 '26	Sale	18.61	2,237	41,631	407,660	Jul 30 04:12 PM
SEKAR KATHIRESAN	Director	Jul 21 '26	Proposed Sale	19.81	30,000	594,414		Jul 21 04:10 PM
SEKAR KATHIRESAN	Director	Jul 20 '26	Proposed Sale	19.58	66,055	1,293,555		Jul 20 04:05 PM
Bergstrom Donald A	President, R&D	Jul 06 '26	Sale	18.71	8,660	162,029	409,897	Jul 08 05:11 PM
Patel Sanjiv	President and CEO	Jul 07 '26	Sale	19.58	48,199	943,736	615,898	Jul 08 05:08 PM
Catinazzo Thomas	Chief Financial Officer	Jul 06 '26	Sale	18.69	17,717	331,131	159,744	Jul 08 05:07 PM
SANJIV PATEL	Director	Jul 07 '26	Proposed Sale	18.90	144,597	2,732,883		Jul 07 04:36 PM
Rahmer Peter	See remarks	Jun 30 '26	Sale	19.09	50,000	954,500	225,857	Jul 02 04:12 PM
PETER RAHMER	Officer	Jun 30 '26	Proposed Sale	19.74	50,000	987,000		Jun 30 04:35 PM
Catinazzo Thomas	Chief Financial Officer	Jun 22 '26	Option Exercise	4.93	169,446	834,669	239,024	Jun 24 04:09 PM
Catinazzo Thomas	Chief Financial Officer	Jun 22 '26	Sale	16.97	187,163	3,176,865	177,461	Jun 24 04:09 PM
Bergstrom Donald A	President, R&D	Jun 22 '26	Option Exercise	4.12	93,456	385,039	512,013	Jun 24 04:09 PM
Bergstrom Donald A	President, R&D	Jun 22 '26	Sale	16.94	93,456	1,583,145	418,557	Jun 24 04:09 PM
DONALD BERGSTROM	Officer	Jun 22 '26	Proposed Sale	15.88	110,646	1,757,058		Jun 22 04:57 PM
THOMAS CATINAZZO	Officer	Jun 22 '26	Proposed Sale	15.88	204,880	3,253,494		Jun 22 04:57 PM
Catinazzo Thomas	Chief Financial Officer	May 14 '26	Sale	12.86	17,717	227,841	195,178	May 14 06:44 PM
THOMAS CATINAZZO	Officer	May 14 '26	Proposed Sale	13.22	37,234	492,233		May 14 04:24 PM
Catinazzo Thomas	Chief Financial Officer	Apr 28 '26	Sale	14.79	972	14,376	212,895	Apr 30 04:22 PM
Rahmer Peter	See remarks	Apr 28 '26	Sale	14.79	753	11,137	275,857	Apr 30 04:22 PM
Bergstrom Donald A	President, R&D	Apr 28 '26	Sale	14.79	1,490	22,037	418,557	Apr 30 04:20 PM
Catinazzo Thomas	Chief Financial Officer	Apr 09 '26	Option Exercise	5.22	1,800	9,396	215,667	Apr 09 08:55 PM
Catinazzo Thomas	Chief Financial Officer	Apr 07 '26	Sale	13.01	17,717	230,498	213,867	Apr 09 08:55 PM
Catinazzo Thomas	Chief Financial Officer	Apr 09 '26	Sale	15.00	1,800	27,000	213,867	Apr 09 08:55 PM
Catinazzo Thomas	Chief Financial Officer	Mar 09 '26	Sale	10.06	17,717	178,233	231,584	Mar 11 04:30 PM
THOMAS CATINAZZO	Officer	Mar 09 '26	Proposed Sale	9.89	53,151	525,663		Mar 09 04:35 PM
Bergstrom Donald A	President, R&D	Jan 27 '26	Sale	7.62	18,895	143,980	422,733	Jan 29 04:22 PM
Bergstrom Donald A	President, R&D	Jan 28 '26	Sale	8.45	2,686	22,697	420,047	Jan 29 04:22 PM
Rahmer Peter	See remarks	Jan 27 '26	Sale	7.62	11,684	89,032	277,964	Jan 29 04:22 PM
Rahmer Peter	See remarks	Jan 28 '26	Sale	8.45	1,354	11,441	276,610	Jan 29 04:22 PM
Catinazzo Thomas	Chief Financial Officer	Jan 27 '26	Sale	7.62	13,820	105,308	250,996	Jan 29 04:20 PM
Catinazzo Thomas	Chief Financial Officer	Jan 28 '26	Sale	8.45	1,695	14,323	249,301	Jan 29 04:20 PM
Patel Sanjiv	President and CEO	Jan 06 '26	Sale	7.82	43,168	337,574	661,041	Jan 07 04:15 PM
Patel Sanjiv	President and CEO	Nov 03 '25	Sale	7.00	62,073	434,511	703,215	Nov 04 04:10 PM
Rahmer Peter	See remarks	Oct 29 '25	Sale	7.50	21,394	160,455	337,469	Oct 30 04:19 PM
Rahmer Peter	See remarks	Oct 28 '25	Sale	7.29	19,135	139,494	358,863	Oct 30 04:19 PM
Catinazzo Thomas	Chief Financial Officer	Oct 28 '25	Sale	7.29	21,664	157,931	313,631	Oct 30 04:15 PM
Bergstrom Donald A	President, R&D	Oct 28 '25	Sale	7.29	30,897	225,239	521,823	Oct 30 04:12 PM
Peter J Rahmer	Officer	Oct 29 '25	Proposed Sale	7.50	21,394	160,436		Oct 29 04:18 PM

KYMR

Kymera Therapeutics Inc

RLAY

Relay Therapeutics Inc

Upgrade your Finviz experience